I'm just a sideline observer here, but a circa $1M package for the CEO of a biotech company that does not have anything on the market, a declining shareprice, and missed (or delayed) milestones seems a bit excessive IMO.
For example, other CEOs of 'high profile' Australian Biotechs receive far less remuneration for argueably greater performance:
Acrux - Richard Treagus $570,888
Alchemia - Peter Smith $526,470
Starpharma - Jackie Fairley $ 437,841
Biota - Peter Cook $654,571
Healthlinx - Nick Gatsios $329,484
analyst reporting getting more pathetic, page-12
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$11.25 |
Change
0.110(0.99%) |
Mkt cap ! $563.8M | |||
| Open | High | Low | Value | Volume |
| $11.15 | $11.36 | $11.15 | $1.189M | 105.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8646 | $11.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.25 | 2541 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| CUV (ASX) Chart |